BriaCell Therapeutics Bilan de santé

Santé financière contrôle des critères 3/6

BriaCell Therapeutics possède un total de capitaux propres de $-2.7M et une dette totale de $0.0, ce qui porte son ratio d'endettement à 0%. Son actif total et son passif total sont $5.9M et de $8.6M.

Informations clés

Ratio d'endettement

US$0

Dette

Ratio de couverture des intérêts	n/a
Argent liquide	US$862.09k
Fonds propres	-US$2.68m
Total du passif	US$8.56m
Total des actifs	US$5.87m

Mises à jour récentes de la santé financière

Recent updates

BriaCell stock rises on license deal for anti-cancer agent

Aug 04

BriaCell partners with Waisman Biomanufacturing to make & supply prostate cancer therapy

Jul 05

BriaCell, Harvard enter research agreement to identify targets for cancer treatments

Jun 29

BriaCell Therapeutics receives proceed of $12.88M from warrant exercises

Jun 10

BriaCell Therapeutics skyrockets 104% on robust overall survival benefit in advanced breast cancer patients

Jun 02

Analyse de la situation financière

Passif à court terme: BCTX a des fonds propres négatifs, ce qui est une situation plus grave que des actifs à court terme ne couvrant pas les passifs à court terme.

Passif à long terme: BCTX a des capitaux propres négatifs, ce qui est une situation plus grave que des actifs à court terme ne couvrant pas les passifs à long terme.

Historique et analyse du ratio d'endettement

Niveau d'endettement: BCTX est sans dette.

Réduire la dette: BCTX a des capitaux propres négatifs, nous n'avons donc pas besoin de vérifier si sa dette a diminué au fil du temps.

Bilan

Analyse des pistes de trésorerie

Pour les entreprises qui ont été en moyenne déficitaires dans le passé, nous évaluons si elles disposent d'au moins un an de trésorerie.

Piste de trésorerie stable: BCTX dispose d'une piste de trésorerie suffisante pour 0 mois sur la base du dernier rapport flux de trésorerie disponible, mais a depuis levé des capitaux supplémentaires.

Prévisions de trésorerie: BCTX devrait disposer d'une marge de trésorerie suffisante pour 0 mois sur la base des estimations de flux de trésorerie disponible, mais a depuis levé des capitaux supplémentaires.

BriaCell Therapeutics Bilan de santé

Santé financière contrôle des critères 3/6

Informations clés

Mises à jour récentes de la santé financière

BriaCell Therapeutics Receives Deficiency Letter from Nasdaq Due to Non-Compliance with the Minimum Bid Price Requirement

BriaCell Therapeutics Receives Letter from Nasdaq Due to Non-Compliance with the Minimum Market Value of Listed Securities Requirement Pursuant to Nasdaq Listing Rule 5550(b)(2)

Recent updates

Briacell Reports Outperforming Metastatic Breast Cancer Patients and Standard-Beating Survival Data

BriaCell Therapeutics Corp. Provides Phase 3 Clinical Engagement Update in Metastatic Breast Cancer Pivotal Study

BriaCell Therapeutics Corp. has filed a Follow-on Equity Offering.

BriaCell Therapeutics Corp. Reports 100% Resolution of Brain Metastasis in Breast Cancer Patient with "Eye-Bulging" Tumor

Insufficient new directors

Price target decreased by 14% to US$15.00

BriaCell Announces FDA-Authorized Expanded Access Policy for Metastatic Breast Cancer Patients

New major risk - Financial data availability

New major risk - Shareholder dilution

BriaCell Therapeutics Corp. has completed a Follow-on Equity Offering in the amount of $8.50425 million.

BriaCell Therapeutics Corp. has filed a Follow-on Equity Offering in the amount of $8.50425 million.

BriaCell Therapeutics Corp. Announces Positive Overall Survival Data of its Phase 2 Clinical Study of Bria-IMT in Combination with an Immune Check Point Inhibitor

BriaCell Announces Positive Pre-IND Meeting with FDA for Bria-PROS+ for Prostate Cancer

BriaCell Therapeutics Receives Deficiency Letter from Nasdaq Due to Non-Compliance with the Minimum Bid Price Requirement

BriaCell Therapeutics Corp. Quadruples Progression Free Survival (Pfs) in Patient with "Eye-Bulging" Metastatic Breast Cancer

BriaCell Therapeutics Receives Letter from Nasdaq Due to Non-Compliance with the Minimum Market Value of Listed Securities Requirement Pursuant to Nasdaq Listing Rule 5550(b)(2)

Briacell Therapeutics Corp. Presents Clinical Efficacy Data At ASCO 2024

BriaCell Therapeutics Corp. Initiates Patient Enrollment in First-In-Human Study of Bria-Ots in Advanced Metastatic Breast Cancer

New minor risk - Shareholder dilution

Independent Director recently bought US$2.0m worth of stock

BriaCell Therapeutics Corp. has completed a Follow-on Equity Offering in the amount of $4.80586 million.

BriaCell Therapeutics Corp. has filed a Follow-on Equity Offering in the amount of $5 million.

BriaCell 2024 AACR Preclinical Poster Confirms Strong Anti-Cancer Activity of Bria-OTS+™ and Bria-PROS+™ Clinical Candidates for Breast and Prostate Cancer

New major risk - Negative shareholders equity

BriaCell Therapeutics Corp. Announces Strong Clinical Data in Breast Cancer Patients; Reports Another Notable Responder Case

Briacell Therapeutics Corp. Announces Lead Prostate Cancer Candidate Bria-Pros+, Initiates Gmp Manufacturing

BriaCell Therapeutics Corp. Reports 71% Central Nervous System Response Rate in Advanced Breast Cancer Patients

BriaCell Therapeutics Corp. Reports Unprecedented Preliminary Survival and Clinical Benefit in Antibody-Drug Conjugate Refractory Patient Subset

BriaCell Therapeutics Corp. Highlights Outstanding Topline Survival and Clinical Benefit Data in Advanced Metastatic Breast Cancer at the 2023 SABCS

BriaCell Therapeutics Corp., Annual General Meeting, Jan 30, 2024

BriaCell Therapeutics Corp. Announces Anew Remarkable Responder in Phase 2 Study of the Bria-IMT Combination Regimen

BriaCell Reports Unprecedented Anti-Tumor Activity of its Next Generation Personalized Breast and Prostate Cancer Immunotherapies in Tumor Models at the 2023 SITC Annual Meeting; FDA Greenlights Bria-OTS™ IND

New minor risk - Share price stability

New major risk - Financial position

BriaCell Therapeutics Corp. Forms Medical Advisory Board of Distinguished Breast Cancer Specialists to Advance its Lead Oncology Candidate

BriaCell Therapeutics Corp. Initiates Pivotal Phase 3 Study of Bria-Imt™ in Advanced Metastatic Breast Cancer

BriaCell Therapeutics Corp. Reports Benchmark-Beating Patient Survival and Clinical Benefit in Advanced Metastatic Breast Cancer

BriaCell Therapeutics Corp. completed the Spin-Off of 33.33% stake in Pre-Clinical Assets of BriaCell Therapeutics Corp.

Briacell Receives National Cancer Institute Grant to Advance Its Bria-Ots™ Immunotherapy for Cancer

FDA Approves BriaCell’s Pivotal Registrational Study Design in Advanced Metastatic Breast Cancer

BriaCell Therapeutics Corp. Announces Positive End of Phase II Meeting with the FDA for Bria-IMT™ Combination in Advanced Metastatic Breast Cancer

Independent Chairman of the Board recently bought US$118k worth of stock

BriaCell Therapeutics Corp., Annual General Meeting, Jan 24, 2023

BriaCell Therapeutics Corp. Reports Positive Breast Cancer Efficacy Data with Bria-IMT™ Immunotherapy Treatment at SITC Annual Meeting

BriaCell Announces Successful Completion of Phase I Portion of Clinical Study in Advanced Breast Cancer; Randomized Phase II Efficacy Evaluation Progressing

BriaCell Therapeutics Corp. Announces New Clinical Trial Site to Bring Novel Cancer Treatments to Advanced Breast Cancer Patients

BriaCell Therapeutics Corp. Secures License for A Promising Novel Anti-Cancer Agent

BriaCell stock rises on license deal for anti-cancer agent

BriaCell partners with Waisman Biomanufacturing to make & supply prostate cancer therapy

BriaCell, Harvard enter research agreement to identify targets for cancer treatments

BriaCell Therapeutics Corp. Receives FDA Fast Track Approval for Targeted Breast Cancer Immunotherapy

BriaCell Advances Preparatory Work for New Bria-OTS Breast Cancer Clinical Trial

High number of new directors

BriaCell Therapeutics Corp. Adds Two Clinical Trial Sites to Accelerate Patient Enrollment

BriaCell Therapeutics Corp. Appoints Alexander Kharazi to Its Scientific Advisory Board

Director recently bought US$433k worth of stock

Briacell Therapeutics Corp. Appoints Giuseppe Del Priore as Chief Medical Officer

Director recently bought US$355k worth of stock

BriaCell Therapeutics Corp.(TSXV:BCT) dropped from S&P/TSX Venture Composite Index

High number of new and inexperienced directors

Investor sentiment deteriorated over the past week

High number of new and inexperienced directors

Investor sentiment improved over the past week

Director Marc Lustig has joined 5th company board

Director Marc Lustig has joined 5th company board

Director Marc Lustig has joined 5th company board

Director Marc Lustig has joined 5th company board

Investor sentiment deteriorated over the past week

Investor sentiment improved over the past week

BriaCell Therapeutics Corp. Announces Phase I/IIa Clinical Trial Combination Study in Advanced Breast Cancer Patients Open for Enrollment

Investor sentiment improved over the past week

Briacell Therapeutics Expands Breast Cancer Platform Technology into Prostate, Melanoma, and Lung Cancers

BriaCell Therapeutics receives proceed of $12.88M from warrant exercises